Comparison of Antibody Forms in Cancer Treatment
Author Information
Author(s): C.-A. Vogel, A. Bischof-Delaloye, J.-P. Mach, A. Pelegrin, N. Hardman, B. Delaloye, F. Buchegger
Primary Institution: Centre Hospitalier Universitaire Vaudois, University of Lausanne, Ciba-Geigy AG
Hypothesis
The study aims to compare the tumor localization capacity of a chimeric anti-CEA monoclonal antibody in its intact form versus its F(ab')2 fragment.
Conclusion
The F(ab')2 fragment showed higher tumor-to-blood ratios compared to the intact monoclonal antibody, suggesting it may be more effective for targeted cancer therapies.
Supporting Evidence
- The intact MAb showed a maximum localization of 64% ID/g at 24 hours, while the F(ab')2 fragment peaked at 57% ID/g at 12 hours.
- F(ab')2 fragments had significantly higher tumor-to-blood ratios compared to intact MAbs at various time points.
- The study utilized a paired labeling technique to ensure accurate comparisons between the two antibody forms.
Takeaway
This study looked at how well two types of cancer-fighting antibodies work in mice. One type worked better at getting to the tumors than the other.
Methodology
The study used nude mice with different human colon cancer xenografts to compare the localization of radiolabeled intact monoclonal antibodies and their F(ab')2 fragments.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
Nude mice, specifically 7-9-week-old male 'Swiss' homozygous nu/nu mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website